Insider Trading April 29, 2026 05:07 PM

Argan Inc. Director William Leimkuhler Executes $3.58 Million Stock Sale

Insider transactions involve direct holdings and two family trusts amid recent earnings reports and expanded share buyback initiatives.

By Priya Menon AGX
Argan Inc. Director William Leimkuhler Executes $3.58 Million Stock Sale
AGX

William F. Leimkuhler, a director at Argan Inc. (NASDAQ: AGX), has completed the sale of common stock totaling $3,582,950. The transactions, which took place on April 28, 2026, encompassed both direct personal holdings and indirect interests held through trusts. This movement in insider ownership comes as Argan Inc. navigates a period of significant price appreciation and recent fiscal reporting updates.

Key Points

  • Director William Leimkuhler sold over $3.5 million in AGX stock through direct and trust holdings.
  • Argan Inc. is aggressively returning capital via an expanded $200 million buyback program and cash dividends.
  • The company's recent quarterly results showed a significant EPS beat but a revenue miss.

On April 28, 2026, William F. Leimkuhler, serving as a director for Argan Inc. (NASDAQ: AGX), executed a series of transactions resulting in the sale of $3,582,950 worth of common stock. These disposals were split between Mr. Leimkuhler's direct ownership and holdings managed via two separate trusts where he acts as Trustee.

Breakdown of Transaction Details

The individual components of the sale are detailed as follows:

  • Direct Holdings: Mr. Leimkuhler sold 5,000 shares of Argan Inc. common stock at an average price point of $617.41 per share. Following this divestment, his direct stake in the company consists of 36,495 shares.
  • Trust Dispositions: Two specific trusts overseen by Mr. Leimkuhler also reduced their positions. The Emily K. Leimkuhler Trust sold 400 shares at a price of $621.14 per share, while the Elizabeth K. Leimkuhler Trust sold 400 shares at $618.61 per share. Post-transaction, both the Emily K. Leimkuhler Trust and the Elizabeth K. Leimkuhler Trust maintain a holding of 500 shares each in Argan Inc.

The overall price range for these combined sales fluctuated between $617.41 and $621.14 per share.

Market Context and Financial Performance

These transactions occur against a backdrop of high valuation and recent corporate developments. Argan Inc. shares have experienced a significant upward trajectory, delivering a 313.5% return over the preceding year. At the time of reporting, the stock was trading at $630.07, which is close to its 52-week high of $683.12. However, according to InvestingPro analysis, the current stock price appears to be overvalued based on its Fair Value assessment.

Looking at recent fiscal data, Argan Inc.'s fourth-quarter performance for fiscal year 2026 showed a divergence in key metrics. The company reported earnings per share (EPS) of $3.47, which was considerably higher than the analyst expectation of $2.13. Conversely, quarterly revenue reached $262.1 million, falling short of the anticipated $271.02 million.

In an effort to return value to shareholders, the Board of Directors has taken several active steps. The company expanded its share repurchase program from $150 million up to $200 million, with the window for this program extending through January 31, 2030. Furthermore, a quarterly cash dividend of $0.50 per common share was declared, payable on April 30, 2026, to stockholders of record as of April 22, 2026.


Key Market Observations

Core Points:

  • Insider Activity and Valuation: The sale by a director during a period where the stock is trading near its 52-week high and potentially overvalued may be noted by market participants.
  • Capital Allocation Strategy: Argan's decision to increase its buyback program to $200 million and maintain dividends indicates a focused effort on shareholder returns within the industrial sector.

Risks and Uncertainties:

  • Revenue Discrepancies: While EPS exceeded forecasts, the failure to meet revenue targets ($262.1 million versus $271.02 million expected) presents an uncertainty regarding top-line growth.
  • Valuation Concerns: The disparity between current trading levels and Fair Value assessments poses a risk for investors evaluating entry points at these price levels.

Risks

  • Revenue shortfall relative to analyst expectations may impact future growth outlooks.
  • Stock valuation currently appears overvalued based on Fair Value assessments despite strong year-over-year returns.

More from Insider Trading

Marcus & Millichap Director Executes Substantial Common Stock Purchase May 4, 2026 Patterson-UTI CEO Executes Multi-Million Dollar Stock Sale Amidst Year-to-Date Surge May 4, 2026 Snowflake Director Michael Speiser Executes $7.18 Million in Stock Sales May 4, 2026 Edwards Lifesciences Executive Executes Stock Transactions Amid Recent Financial Growth May 4, 2026 Entrada Therapeutics President and COO Executes Stock Sale via Rule 10b5-1 Plan May 4, 2026